Product Description
Fluphenazine is a medication that treats schizophrenia. It is also known as a first generation antipsychotic (FGA) or typical antipsychotic. Fluphenazine rebalances dopamine to improve thinking, mood, and behavior. (Sourced from: https://www.nami.org/About-Mental-Illness/Treatments/Mental-Health-Medications/Types-of-Medication/Fluphenazine-(Prolixin))
Mechanisms of Action: DR Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intramuscular, Oral, Intravenous
FDA Designation: *
Approval Status: Approved
Approved Countries: Argentina | Bangladesh | Bosnia | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Czech | Dominican Republic | Egypt | France | Hong Kong | Hungary | India | Indonesia | Ireland | Israel | Italy | Lebanon | Lithuania | Malaysia | Malta | Mexico | Morocco | New Zealand | Pakistan | Peru | Philippines | Portugal | Russia | Serbia | Slovakia | Slovenia | Spain | Sri Lanka | Sweden | Taiwan | Thailand | Turkey | Ukraine | United Kingdom | United States | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
09/22/2023 |
News Article |
FLuphenazine Hydrochloride Market Investor, Latest Trends, Industry Growth, Size, Segmentation, Future Demands, by Regional Forecast to 2031 |
|
09/13/2023 |
News Article |
2023, Residential Zoning System Market Growth Trend, Size, Share and Forecast [2030] |
|
04/17/2023 |
News Article |
Endo Announces Launch of Argatroban Injection Through Premier's ProRx® Private-Label Program |
|
04/17/2023 |
News Article |
Endo Announces Launch of Argatroban Injection Through Premier's ProRx® Private-Label Program |